SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-046296
Filing Date
2024-02-26
Accepted
2024-02-26 17:01:00
Documents
17
Period of Report
2024-02-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d796872d8k.htm   iXBRL 8-K 52365
2 EX-2.1 d796872dex21.htm EX-2.1 481432
3 EX-10.1 d796872dex101.htm EX-10.1 68838
4 EX-99.1 d796872dex991.htm EX-99.1 17929
  Complete submission text file 0001193125-24-046296.txt   881955

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ngm-20240225.xsd EX-101.SCH 2844
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20240225_lab.xml EX-101.LAB 17235
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20240225_pre.xml EX-101.PRE 10809
19 EXTRACTED XBRL INSTANCE DOCUMENT d796872d8k_htm.xml XML 3556
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38853 | Film No.: 24679956
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)